Microbiome et santé humaine : avancées technologiques pour de nouvelles perspectives Impact of Gut Microbiota on the Efficacy of Anticancer Treatments Présenté par Bertrand Routy (MD) - Institut Gustave Roussy U1015 - Villejuif ABSTRACT Inhibition of immune regulatory checkpoints, such as CTLA-4 and PD-1/PDL-1 are at the forefront of cancer treatment. The limits of these monoclonal antibodies (mAb) are the unpredictable efficacy and the immune related toxicities. Our team demonstrated that intestinal commensals were part of the answer; specific mucosal dysbiosis could dictate sensitivity or resistance to immune checkpoint inhibitors. We worked on the first-in-class immune checkpoint blocker (ICB), anti-CTLA-4 mAb/ipilimumab, and showed the mandatory role of microbiota (Bacteroidales and Burkholderiales) in its antitumor immune effects and the prophylactic role of such commensals against subclinical colitis in mice (Vétizou M, Science 2015). In parallel, another group demonstrated the importance of Bifidobacterium in maturing intratumoral dendritic cells that allow the expansion of anti-cancer T cells in the tumor beds and their activation with anti-PDL-1 mAb. (Sivan A, Science 2015) We developed in collaboration with Institut National de la Recherche en Agroalimentaire a novel diagnosis tool based on metagenomic signatures of the feces of more than 100 lung and renal cell cancer patients, to predict response/resistance to PD1 inhibitor (Nivolumab). To confirm this signature, we performed fecal microbial transplantation from patients’ feces in germ free mice. Furthermore, for patients’ feces lacking the most immunogenic bacteria and being resistant to PD1, in our germ free model bacterial compensation restored the activity of PD1. Our objective is to provide adjuvant compensatory therapies based on administration of Oncobax i.e. live commensal bacteria to promote clinical responses. KEY WORDS Immune checkpoint inhibitors, lung cancer, kidney cancer